Inxmed (shanghai) Co., Ltd.
Clinical trials sponsored by Inxmed (shanghai) Co., Ltd., explained in plain language.
-
New pill combo takes on hard-to-treat lung cancer in major trial
Disease control Recruiting nowThis phase 3 trial tests two oral drugs (IN10018 and D-1553) against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 400 participants who have not had prior treatment will be randomly assig…
Phase: PHASE3 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New drug duo targets hard-to-treat KRAS G12D cancers
Disease control Recruiting nowThis study tests two drugs, IN10018 and RNK08954, given together to people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or met…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control Recruiting nowThis study tests a new drug called IN10018 combined with standard chemotherapy in people with a tough-to-treat type of ovarian cancer that no longer responds to platinum-based drugs. About 150 adults will take part to see if the combination is safe and shrinks tumors. The goal is…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:05 UTC